Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium Journal Article
| Authors: | Villaruz, L. C.; Socinski, M. A.; Abberbock, S.; Berry, L. D.; Johnson, B. E.; Kwiatkowski, D. J.; John Iafrate, A.; Varella-Garcia, M.; Franklin, W. A.; Camidge, D. R.; Sequist, L. V.; Haura, E. B.; Ladanyi, M.; Kurland, B. F.; Kugler, K.; Minna, J. D.; Bunn, P. A.; Kris, M. G. |
| Article Title: | Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium |
| Abstract: | BACKGROUND: The advent of effective targeted therapy for BRAFV600E-mutant lung adenocarcinomas necessitates further exploration of the unique clinical features and behavior of advanced-stage BRAF-mutant lung adenocarcinomas. METHODS: Data were reviewed for patients with advanced lung adenocarcinomas enrolled in the Lung Cancer Mutation Consortium whose tumors underwent testing for mutations in epidermal growth factor receptor ( EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), human epidermal growth factor receptor 2 ( HER2), AKT1, BRAF, dual-specificity mitogen-activated protein kinase kinase 1 ( MEK1), neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS), and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit a (PIK3CA); for anaplastic lymphoma kinase (ALK) translocations; and for MET amplification. RESULTS: Twenty-one BRAF mutations were identified in 951 patients with adenocarcinomas (2.2%; 95% confidence interval [CI], 1.4%-3.4%): 17 (81%; 95% CI, 60%-92%) were BRAFV600E mutations, and 4 were non-BRAFV600E mutations. Among the 733 cases tested for all 10 genes, BRAF mutations were more likely to occur than most other genotypic abnormalities in current or former smokers (BRAF vs sensitizing EGFR, 82% vs 36%, mid-P < .001; BRAF vs ALK, 39%, mid-P = .003; BRAF vs other mutations, 49%, mid-P = .02; BRAF vs patients with more than 1 oncogenic driver [doubleton], 46%, mid-P = .04.) The double-mutation rate was 16% among patients with BRAF mutations but 5% among patients with other genomic abnormalities (mid-P = .045). Differences were not found in survival between patients with BRAF mutations and those with other genomic abnormalities (P > .20). CONCLUSIONS: BRAF mutations occurred in 2.2% of advanced-stage lung adenocarcinomas, were most commonly V600E, and were associated with distinct clinicopathologic features in comparison with other genomic subtypes and with a high mutation rate in more than 1 gene. These findings underscore the importance of comprehensive genomic profiling in assessing patients with advanced lung adenocarcinomas. |
| Keywords: | adult; human tissue; aged; middle aged; gene mutation; major clinical study; overall survival; advanced cancer; epidermal growth factor receptor 2; smoking; mutational analysis; lung adenocarcinoma; gene rearrangement; mutation rate; oncogene k ras; b raf kinase; braf; akt1 gene; braf gene; oncogene neu; anaplastic lymphoma kinase; molecularly targeted therapy; oncogene n ras; selumetinib; crizotinib; met gene; clinicopathologic features; lung adenocarcinomas; cancer prognosis; very elderly; human; male; female; article; lung cancer mutation consortium; phosphatidylinositol 4,5 bisphosphate 3 kinase catalytic subunit alpha gene; genomic profiling; anaplastic lymphoma kinase gene; dual specificity mitogen activated protein kinase kinase 1 gene |
| Journal Title: | Cancer |
| Volume: | 121 |
| Issue: | 3 |
| ISSN: | 0008-543X |
| Publisher: | Wiley Blackwell |
| Date Published: | 2015-02-01 |
| Start Page: | 448 |
| End Page: | 456 |
| Language: | English |
| DOI: | 10.1002/cncr.29042 |
| PROVIDER: | scopus |
| PMCID: | PMC4305000 |
| PUBMED: | 25273224 |
| DOI/URL: | |
| Notes: | Export Date: 2 March 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work